Drug formularies.
What changed between versions
The prohibition on mid-year formulary changes was narrowed. The original version prohibited removing a drug, moving it to a higher cost tier, or imposing new utilization management requirements. The amended version narrows the core prohibition to moving a drug to a higher cost tier, while allowing other changes through newly added exceptions.
The bill no longer amends Section 1367.22 (the existing continuity-of-coverage provision that prohibited plans from excluding a drug previously approved for an enrollee's condition). That protection is partially replaced by the new continuity right in Section 1367.208(c), but only applies to same-class drug switches rather than all previously approved drugs.
New exceptions allow plans to replace a covered drug with another drug in the same class (with cost sharing no higher than before), replace a brand name drug with a generic of the same class or same drug (with lower cost sharing required), and add biosimilar or interchangeable biologic products at equal or lower net cost.
If a plan requires an enrollee to switch to a different drug in the same class mid-year, the enrollee may remain on the previously covered drug for the rest of the plan year if it was previously approved, appropriately prescribed, and considered safe and effective. The plan must notify the enrollee and provider at least 90 days before implementing the change.
If a plan fails to meet the 72-hour or 24-hour authorization timelines, an enrollee may request and the plan must provide 90 days of transitional coverage for the previously covered drug.
The DMHC must use existing data and authority to collect data from plans and annually publish on its website and submit to the Legislature an aggregated report including: number of nonformulary authorization requests, approvals, denials, appeals and outcomes, and independent medical reviews.
Section 1367.24 now defines 'expeditious process' for nonformulary drug authorization as approval within 72 hours for nonurgent requests or 24 hours if exigent circumstances exist, measured from receipt of the request.
The Department of Managed Health Care director is now explicitly authorized to investigate and take enforcement action against plans for noncompliance, with penalties subject to notice and opportunity for a hearing. Plans may also submit information about their overall compliance record for consideration in penalty determinations.
The fiscal committee determination changed from 'no' to 'yes,' indicating the bill now has a state fiscal impact requiring fiscal committee review. The state-mandated local program designation is now clearly 'yes.'